This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Mesalamine; 5-aminosalicylic acid (5-ASA); Salofalk, MAX-002
Description: The active component of Canasa is 5-ASA, a drug that acts to suppress inflammatory bowel disease. The mode of action of 5-ASA is still under investigation with several biochemical mechanisms being proposed. At present, the action of 5-ASA in treating inflammatory bowel disease appears to be associated with the metabolism of arachidonic acid. Studies suggest that interference of 5-ASA with either leukotriene or prostaglandin metabolism may play a major role in suppressing the inflammatory response mechanism.
In November 2007, Axcan Pharma announced that it entered into an agreement for Axcan to be acquired by TPG Capital and its affiliates in an all-cash transaction with a total value of approximately US$1.3 billion.
Aptalis and Forest
In January 2014, Aptalis announced that it has signed a definitive agreement to be acquired by Forest Laboratories. Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash, pending required reviews by anti-trust authorities in the US and Canada. Forest expects to use a combination of cash on hand and debt to fund the transaction.
In February 2014, Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will now begin combined operations, with Aptalis operating as a subsidiary of Forest Laboratories.
Forest and Actavis
In February 2014, Actavis and...See full deal structure in Biomedtracker
Pink Sheet Axcan Pharma Canasa
Additional information available to subscribers only: